Ranbaxy forfeits exclusivity on generic Provigil
04:52 EDT 17 Aug 2012 | GaBI online
As part of Ranbaxy’s consent decree with FDA, signed in January 2012, the Indian generics major had to agree to relinquish 180-day marketing exclusivity on three pending generic drug applications [1]. Now analysts believe that generic Provigil (mod..
Original Article: Ranbaxy forfeits exclusivity on generic Provigil
More From BioPortfolio on "Ranbaxy forfeits exclusivity on generic Provigil"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
